Pharmos(PARS) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Microcap & Penny Stocks : Pharmos(PARS)

PARS 2.700

+13.6%

Jan 21 4:00 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Tony van Werkhooven who wrote (1021)	7/16/1998 9:32:00 AM
From: ROBERT M. SILVER	Read Replies (1) of 1491

Dear Tony, Thank you for your E mail message. You have got it right. Bausch & Lomb (BOL) loaned Pharmos $5,000,000 so they would not go broke while waiting approval for Lotemax, and Alerex to be approved by the F.D.A. This was a loan that has to be paid back. They have arrived at a formula out of the remissions they are getting from the pharmacies as to how much is held back for repayment of the loan and how much is remitted to Pharmos as cash flow and income. My understanding is that Pharmos is getting 29% of the revenue from the sales of the drugs. But you are right, it should be disclosed in the 10Q which will be filed in August. There is so much anticipation for the first sales in June that the tendency is for the shareholders to be disappointed when the number will come in very small. I expect a number much less than $250,000. It takes time to stock pharmacies with new drugs, especially since there are several similar products on the market. Short selling has depressed the value of the stock. It is going to take buying demand to raise its value and cause the shorts to cover. News on the Hu-211 trials will be the ticket. Thanks for writing. Robert Silver

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next